441 related articles for article (PubMed ID: 23973099)
21. The efficacy of routine use of recombinant human bone morphogenetic protein-2 in occipitocervical and atlantoaxial fusions of the pediatric spine: a minimum of 12 months' follow-up with computed tomography.
Sayama C; Hadley C; Monaco GN; Sen A; Brayton A; Briceño V; Tran BH; Ryan SL; Luerssen TG; Fulkerson D; Jea A
J Neurosurg Pediatr; 2015 Jul; 16(1):14-20. PubMed ID: 25860982
[TBL] [Abstract][Full Text] [Related]
22. Bone Morphogenetic Proteins in Spinal Surgery: What Is the Fusion Rate and Do They Cause Cancer?
Malham GM; Giles GG; Milne RL; Blecher CM; Brazenor GA
Spine (Phila Pa 1976); 2015 Nov; 40(22):1737-42. PubMed ID: 26730525
[TBL] [Abstract][Full Text] [Related]
23. Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine and incidence of cancer.
Sayama C; Willsey M; Chintagumpala M; Brayton A; Briceño V; Ryan SL; Luerssen TG; Hwang SW; Jea A
J Neurosurg Pediatr; 2015 Jul; 16(1):4-13. PubMed ID: 25860984
[TBL] [Abstract][Full Text] [Related]
24. Revision surgery after interbody fusion with rhBMP-2: a cautionary tale for spine surgeons.
Rodgers SD; Marascalchi BJ; Grobelny BT; Smith ML; Samadani U
J Neurosurg Spine; 2013 Jun; 18(6):582-7. PubMed ID: 23560709
[TBL] [Abstract][Full Text] [Related]
25. Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2--but what is the cost?
Mannion RJ; Nowitzke AM; Wood MJ
Spine J; 2011 Jun; 11(6):527-33. PubMed ID: 20739225
[TBL] [Abstract][Full Text] [Related]
26. Accelerating lumbar fusions by combining rhBMP-2 with allograft bone: a prospective analysis of interbody fusion rates and clinical outcomes.
Slosar PJ; Josey R; Reynolds J
Spine J; 2007; 7(3):301-7. PubMed ID: 17482113
[TBL] [Abstract][Full Text] [Related]
27. RhBMP-2-induced radiculitis in patients undergoing transforaminal lumbar interbody fusion: relationship to dose.
Villavicencio AT; Burneikiene S
Spine J; 2016 Oct; 16(10):1208-1213. PubMed ID: 27343729
[TBL] [Abstract][Full Text] [Related]
28. Complications With the Use of BMP-2 in Scaphoid Nonunion Surgery.
Brannan PS; Gaston RG; Loeffler BJ; Lewis DR
J Hand Surg Am; 2016 May; 41(5):602-8. PubMed ID: 27013317
[TBL] [Abstract][Full Text] [Related]
29. Is it safe to use recombinant human bone morphogenetic protein in posterior cervical fusion?
Hiremath GK; Steinmetz MP; Krishnaney AA
Spine (Phila Pa 1976); 2009 Apr; 34(9):885-9. PubMed ID: 19531997
[TBL] [Abstract][Full Text] [Related]
30. High-dose rhBMP-2 for adults: major and minor complications: a study of 502 spine cases.
Mesfin A; Buchowski JM; Zebala LP; Bakhsh WR; Aronson AB; Fogelson JL; Hershman S; Kim HJ; Ahmad A; Bridwell KH
J Bone Joint Surg Am; 2013 Sep; 95(17):1546-53. PubMed ID: 24005194
[TBL] [Abstract][Full Text] [Related]
31. A comparison of radiographic and clinical outcomes of anterior lumbar interbody fusion performed with either a cellular bone allograft containing multipotent adult progenitor cells or recombinant human bone morphogenetic protein-2.
Lee DD; Kim JY
J Orthop Surg Res; 2017 Aug; 12(1):126. PubMed ID: 28841904
[TBL] [Abstract][Full Text] [Related]
32. rhBMP-2 for posterolateral instrumented lumbar fusion: a multicenter prospective randomized controlled trial.
Hurlbert RJ; Alexander D; Bailey S; Mahood J; Abraham E; McBroom R; Jodoin A; Fisher C
Spine (Phila Pa 1976); 2013 Dec; 38(25):2139-48. PubMed ID: 24296479
[TBL] [Abstract][Full Text] [Related]
33. The perioperative cost of Infuse bone graft in posterolateral lumbar spine fusion.
Glassman SD; Carreon LY; Campbell MJ; Johnson JR; Puno RM; Djurasovic M; Dimar JR
Spine J; 2008; 8(3):443-8. PubMed ID: 17526436
[TBL] [Abstract][Full Text] [Related]
34. Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion.
Akamaru T; Suh D; Boden SD; Kim HS; Minamide A; Louis-Ugbo J
Spine (Phila Pa 1976); 2003 Mar; 28(5):429-34. PubMed ID: 12616152
[TBL] [Abstract][Full Text] [Related]
35. Repeat use of human recombinant bone morphogenetic protein-2 for second level lumbar arthrodesis.
Singh K; Dumonski M; Stanley T; Ponnappan R; Phillips FM
Spine (Phila Pa 1976); 2011 Feb; 36(3):192-6. PubMed ID: 20634780
[TBL] [Abstract][Full Text] [Related]
36. Complications associated with single-level transforaminal lumbar interbody fusion.
Rihn JA; Patel R; Makda J; Hong J; Anderson DG; Vaccaro AR; Hilibrand AS; Albert TJ
Spine J; 2009 Aug; 9(8):623-9. PubMed ID: 19482519
[TBL] [Abstract][Full Text] [Related]
37. Prospective, randomized, controlled trial of silicate-substituted calcium phosphate versus rhBMP-2 in a minimally invasive transforaminal lumbar interbody fusion.
Nandyala SV; Marquez-Lara A; Fineberg SJ; Pelton M; Singh K
Spine (Phila Pa 1976); 2014 Feb; 39(3):185-91. PubMed ID: 24253788
[TBL] [Abstract][Full Text] [Related]
38. The efficacy of rhBMP-2 for posterolateral lumbar fusion in smokers.
Glassman SD; Dimar JR; Burkus K; Hardacker JW; Pryor PW; Boden SD; Carreon LY
Spine (Phila Pa 1976); 2007 Jul; 32(15):1693-8. PubMed ID: 17621221
[TBL] [Abstract][Full Text] [Related]
39. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion.
Shields LB; Raque GH; Glassman SD; Campbell M; Vitaz T; Harpring J; Shields CB
Spine (Phila Pa 1976); 2006 Mar; 31(5):542-7. PubMed ID: 16508549
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of bone morphogenetic protein-2 in mature adults: posterolateral non-instrument-assisted lumbar decompression and fusion.
Hamilton DK; Jones-Quaidoo SM; Sansur C; Shaffrey CI; Oskouian R; Jane JA
Surg Neurol; 2008 May; 69(5):457-61; discussion 461-2. PubMed ID: 18207557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
